Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)
Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%
Abbott Laboratories pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Abbott Laboratories's pe ratio was 35.1× on Nov 11, 2026, against 16.1× a year earlier. Over the last 5 years it ranged from 13.7× to 38.9×, with a median of 30.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 35.1× | +19.5 |
| 2025 | Dec 31, 2025 | 15.7× | −18.7 |
| 2024 | Dec 31, 2024 | 34.4× | −3.1 |
| 2023 | Dec 29, 2023 | 37.4× | +12.7 |
| 2022 | Dec 30, 2022 | 24.8× | −10.1 |
| 2021 | Dec 31, 2021 | 34.9× | −23.0 |
| 2020 | Dec 31, 2020 | 57.9× | +10.7 |
| 2019 | Dec 31, 2019 | 47.2× | −103.5 |
| 2018 | Dec 31, 2018 | 150.7× | +105.8 |
| 2017 | Dec 29, 2017 | 44.9× | +2.7 |
| 2016 | Dec 30, 2016 | 42.2× | +27.2 |
| 2015 | Dec 31, 2015 | 15.0× | −20.5 |
| 2014 | Dec 31, 2014 | 35.4× | +15.4 |
| 2013 | Dec 31, 2013 | 20.1× | +4.1 |
| 2012 | Dec 31, 2012 | 16.0× | −3.4 |
| 2011 | Dec 30, 2011 | 19.5× | +3.6 |
| 2010 | Dec 31, 2010 | 15.9× | +1.2 |
| 2009 | Dec 31, 2009 | 14.7× | – |
See a number that looks wrong?